Jessica Joan Morrell, CNP | |
409 E Meadowlark Cir, Brandon, SD 57005-1082 | |
(605) 254-4335 | |
(844) 550-1755 |
Full Name | Jessica Joan Morrell |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 409 E Meadowlark Cir, Brandon, South Dakota |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1548402340 | NPI | - | NPPES |
6836360 | Medicaid | SD |
Mailing Address | Practice Location Address |
---|---|
Jessica Joan Morrell, CNP 2400 S. Minnesota Ave, Ste 100, Sioux Falls, SD 57105-3762 Ph: (605) 322-7510 | Jessica Joan Morrell, CNP 409 E Meadowlark Cir, Brandon, SD 57005-1082 Ph: (605) 254-4335 |
News Archive
Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today unveiled Microcyn Solution with preservatives, at the New York Podiatric Clinical Conference & Exhibition being held in downtown Manhattan, January 29-31.
Students with symptoms of sleep disorders are more likely to receive bad grades in classes such as math, reading and writing than peers without symptoms of sleep disorders, according to a research abstract presented at SLEEP 2007, the 21st Annual Meeting of the Associated Professional Sleep Societies (APSS).
In her latest Kaiser Health News consumer column, Michelle Andrews writes: "According to the Department of Health and Human Services, the key is whether the retiree health plan is made up only of retirees and their dependents or a mix of both active and retired employees and dependents.
Spectrum Pharmaceuticals today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug Administration for SPI-014 (previously referred to as RENAZORB), a second-generation lanthanum-based nanoparticle phosphate binding agent, that has the potential to treat hyperphosphatemia in patients with Stage 5 chronic kidney disease, or end-stage renal disease (ESRD).
Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.
› Verified 8 days ago
Pamela S. Gabbert, CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 608 N. Yellowstone Dr., Brandon, SD 57005 Phone: 605-941-5349 | |
Ann J Bossman, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1101 E Holly Blvd, Brandon, SD 57005 Phone: 605-582-3853 Fax: 605-582-3855 |